GlassScriptPhysician profile
Jaime Beth Simon
NPI 1326307026
$4,987.54
in general payments reported to CMS, 2019-2025
40 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $684 · 2021: $948 · 2022: $1,002 · 2023: $676 · 2024: $404 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $819.41 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $818.13 | 2019-2025 | Ozempic, Wegovy, Saxenda |
| Abbvie INC. | $581.79 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Glaxosmithkline, LLC. | $472.47 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $418.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $271.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $165.01 | 2019-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $150.92 | 2019-2023 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.58 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $103.13 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $96.50 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $89.48 | 2021-2024 | Xarelto |
| Allergan, INC. | $69.15 | 2019-2020 | |
| Amgen INC. | $68.07 | 2019-2023 | Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $66.60 | 2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $48.76 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.74 | 2021 | |
| Genentech USA, INC. | $43.73 | 2020-2021 | |
| Bardy Diagnostics, INC. | $41.59 | 2020-2022 | |
| Esperion Therapeutics, INC. | $39.64 | 2020-2023 | Nexletol |
| Inspire Medical Systems, INC. | $34.90 | 2025 | Inspire |
| Eisai INC. | $31.73 | 2021 | |
| Supernus Pharmaceuticals, INC. | $29.36 | 2021 | |
| Pfizer INC. | $27.78 | 2019-2023 | |
| Phadia US INC. | $27.41 | 2021-2024 | Immunocap |
| Novavax INC | $26.40 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Dynavax Technologies Corporation | $25.08 | 2023 | Heplisav-B |
| Renalytix Ai, INC. | $24.50 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Xeris Pharmaceuticals, INC. | $22.90 | 2025 | Keveyis |
| E.R. Squibb & Sons, L.L.C. | $21.52 | 2024 | Eliquis |
| Bausch Health US, LLC | $20.38 | 2022 | |
| Teleflex LLC | $20.18 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.44 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $18.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.16 | 2022 | |
| Shield Therapeutics INC | $17.71 | 2023 | Accrufer |
| Hikma Pharmaceuticals USA | $17.60 | 2020 | |
| Seqirus USA INC | $16.62 | 2019 | |
| Astellas Pharma US INC | $16.02 | 2021 | |
| Alfasigma USA, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.